Alterity Therapeutics
ATHE
10 hedge funds and large institutions have $194K invested in Alterity Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 9 → 10 (+1)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
47% less capital invested
Capital invested by funds: $364K → $194K (-$170K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$35.2K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$33.6K |
| 3 |
CA
CoreCap Advisors
Southfield,
Michigan
|
+$40 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$112K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$47K |
| 3 |
VF
Virtu Financial
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $108K | -$112K | -58,169 | -53% |
|
|
2
Citadel Advisors
Miami,
Florida
| $37.5K | +$35.2K | +18,279 | New |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| $35.7K | +$33.6K | +17,425 | New |
|
|
TLCM
4
Twin Lakes Capital Management
Redwood Shores,
California
| $12.3K | – | – | – |
|
|
PCA
5
Providence Capital Advisors
Charlotte,
North Carolina
| $414 | – | – | – |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $165 | – | – | – |
|
|
SWM
7
Sugarloaf Wealth Management
Duluth,
Georgia
| $68 | – | – | – |
|
|
CA
8
CoreCap Advisors
Southfield,
Michigan
| $43 | +$40 | +21 | New |
|
|
SPIA
9
Steward Partners Investment Advisory
New York
| $12 | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $4 | +$4 | +2 | New |
|
|
11
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$47K | -14,907 | Closed |
|
|
VF
12
Virtu Financial
New York
| – | -$27K | -10,799 | Closed |
|
ATHE Hedge Fund Activity: Q1 2024 in Review
10 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2024, worth a combined $194K — down 47% from $364K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ATHE positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $35.2K. The largest seller was Morgan Stanley, cutting an estimated $112K.
- 10 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2024, up from 9 in Q4 2023.
- Funds reported $194K of Alterity Therapeutics stock for Q1 2024, down 47% quarter-over-quarter.
- 4 funds opened new Alterity Therapeutics positions in Q1 2024 and 2 closed out, a net change of +2 holders.
- The largest Alterity Therapeutics buyer in Q1 2024 was Citadel Advisors, an estimated $35.2K added.
- The largest Alterity Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $112K sold.
Based on aggregated 13F filings for Q1 2024.